Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines

Blood Cancer Journal

Volumn 4, Issue 1, 2014, Pages

  Valdez, B C ^a   Zander, A R ^b   Song, G ^a   Murray, D ^c   Nieto, Y ^a   Li, Y ^a   Champlin, R E ^a   Andersson, B S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

apoptosis; clofarabine; edelfosine; gemcitabine; lymphoma; synergism

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CASPASE 8; CLOFARABINE; EDELFOSINE; GEMCITABINE; HISTONE H2AX; KAP1 PROTEIN; MEMBRANE PROTEIN; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DIMERIZATION; DRUG POTENTIATION; HETERODIMERIZATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LYMPHOMA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRESS; WESTERN BLOTTING;

EID: 84892397621     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.69     Document Type: Article

References (52)

1. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J et al. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol 2013; 41: 719-730.
2. Andreesen R, Modolell M, Weltzien HU, Eibl H, Common HH, Lo? hr GW et al. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res 1978; 38: 894-899.
3. Chabot MC, Wykle RL, Modest EJ, Daniel LW. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methylrac-glycero-3-phosphocholine. Cancer Res 1989; 49: 4441-4445.
4. Zeller WJ, Bauer S, Remmele T, Wowra B, Sturm V, Stricker H. Interstitial chemotherapy of experimental gliomas. Cancer Treat Rev 1990; 17: 183-189.
5. Dietzfelbinger HF, Ku?hn D, Zafferani M, Hanauske AR, Rastetter JW, Berdel WE. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Cancer Res 1993; 53: 3747-3751.
6. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M et al. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010; 16: 2046-2054.
7. Gajate C, Matos-da-Silva M, Dakir el-H, Fonteriz RI, Alvarez J, Mollinedo F. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene 2012; 31: 2627-2639.
8. Berdel WE. Ether lipids and derivatives as investigational anticancer drugs. A brief review. Onkologie 1990; 13: 245-250.
9. Drings P, Gu?nther IU, Gatzemeier U, Ulbrich F, Khanavkar B, Schreml W et al. Final evaluation of a Phase II study on the effect of edelfosine (an ether lipid) in advanced non-small cell bronchogenic carcinoma. Onkologie 1992; 15: 375-382.
10. Mollinedo F, Gajate C, Martn-Santamara S, Gago F. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem 2004; 11: 3163-3184.
11. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719.
12. Na HK, Surh YJ. The antitumor ether lipid edelfosine (ET-18-O-CH3) induces apoptosis in H-ras transformed human breast epithelial cells: by blocking ERK1/2 and p38 mitogen-activated protein kinases as potential targets. Asia Pac J Clin Nutr 2008; 17: 204-207.
13. van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008; 14: 2061-2074.
14. Gajate C, Mollinedo F. Lipid rafts and Fas/CD95 signaling in cancer hemotherapy. Recent Pat Anticancer Drug Discov 2011; 6: 274-283.
15. Nieto-Miguel T, Fonteriz RI, Vay L, Gajate C, Lo? pez-Herna?ndez S, Mollinedo F. Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res 2007; 67: 10368-10378.
16. Burgeiro A, Pereira CV, Carvalho FS. Edelfosine and perifosine disrupt hepatic mitochondrial oxidative phosphorylation and induce the permeability transition. Mitochondrion 2013; 13: 5-35.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
19. Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 2011; 81: 222-232.
20. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 2012; 40: 800-810.
21. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008; 27: 6522-6537.
22. Renis M, Cardile V, Palumbo M, Russo A. ET-18-OCH(3)-induced cytotoxicity and DNA damage in rat astrocytes. Int J Dev Neurosci 2000; 18: 545-555.
23. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868.
24. Ziv Y, Bielopolski D, Galanty Y, Lukas C, Taya Y, Schultz DC et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM-and KAP-1 dependent pathway. Nat Cell Biol 2006; 8: 870-876.
25. Munemasa Y, Suzuki T, Aizawa K, Miyamoto S, Imai Y, Matsumura T et al. Promoter region-specific histone incorporation by the novel histone chaperone ANP32B and DNA-binding factor KLF5. Mol Cell Biol 2008; 28: 1171-1181.
26. Shen SM, Yu Y, Wu YL, Cheng JK, Wang LS, Chen GQ. Downregulation of ANP32B, a novel substrate of caspase-3, enhances caspase-3 activation and apoptosis induction in myeloid leukemic cells. Carcinogenesis 2010; 31: 419-426.
27. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 2003; 8: 115-128.
28. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
29. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
30. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-874.
31. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 2002; 277: 10244-10250.
32. Reis-Sobreiro M, Roue? G, Moros A, Gajate C, de la Iglesia-Vicente J, Colomer D et al. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J 2013; 3: e118.
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
34. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-6551.
35. Lau E, Ronai ZA. ATF2-at the crossroad of nuclear and cytosolic functions. J Cell Sci 2012; 125: 2815-2824.
36. Fuchs SY, Tappin I, Ronai Z. Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J Biol Chem 2000; 275: 12560-12564.
37. Abdel-Hafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL et al. Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p42 and p54 microtubule-associated protein kinases. Mol Endoc 1992; 6: 2079-2089.
38. Falvo JV, Parekh BS, Lin CH, Fraenkel E, Maniatis T. Assembly of a functional beta interferon enhanceosome is dependent on ATF-2/c-Jun heterodimer orientation. Mol Cell Biol 2000; 20: 4814-4825.
39. Hayakawa J, Mittal S, Wang Y, Korkmaz KS, Adamson E, English C et al. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 2004; 16: 521-535.
40. Gajate C, Gonzalez-Camacho F, Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One 2009; 4: e5044.
41. Kuerschner L, Richter D, Hannibal-Bach HK, Gaebler A, Shevchenko A, Ejsing CS et al. Exogenous ether lipids predominantly target mitochondria. PLoS One 2012; 7: e31342.
42. Gajate C, Santos-Beneit AM, Macho A, Md Lazaro, Hernandez-De Rojas A, Modolell M et al. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int J Cancer 2000; 86: 208-218.
43. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991; 176: 586-592.
44. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-3543.
45. Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, Koretzky G et al. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol 1998; 160: 134-144.
46. Towers E, Gilley J, Randall R, Hughes R, Kristiansen M, Ham J. The proapoptotic dp5 gene is a direct target of the MLK-JNK-c-Jun pathway in sympathetic neurons. Nucleic Acids Res 2009; 37: 3044-3060.
47. Song B, Xie B, Wang C, Li M. Caspase-3 is a target gene of c-Jun:ATF2 heterodimers during apoptosis induced by activity deprivation in cerebellar granule neurons. Neurosci Lett 2011; 505: 76-81.
48. Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD. Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. EMBO J 2006; 25: 1058-1069.
49. Hayakawa J, Depatie C, Ohmichi M, Mercola D. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 2003; 278: 20582-20592.
50. Bhoumik A, Lopez-Bergami P, Ronai Z. ATF2 on the double-activating transcription factor and DNA damage response protein. Pigment Cell Res 2007; 20: 498-506.
51. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
52. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.